Abstract
Inflammatory bowel diseases, namely Crohn's disease and ulcerative colitis, are currently considered multifactorial pathologies in which various combined environmental factors act on genetic background, giving rise to chronic inflammation of the gastrointestinal tract. Ulcerative colitis is an inflammation of the colon caused by a dysregulated immune response to host intestinal microbiota in genetically susceptible subjects. Ulcerative colitis has a strong impact on patients' quality of life, as well as high costs for the health-care system. A great interest on the role of intestinal microbiota modulation in ulcerative colitis is emerging. Several studies have shown an improvement of inflammatory markers and symptoms in ulcerative colitis patients through treatments with probiotics and prebiotics separately. Despite the low number of studies on the treatment of ulcerative colitis by specific strains of probiotics plus selected prebiotics, i.e. synbiotics, the results are promising, even if discordant. The mechanism of action in synbiotics supplementation is still unclear and needs more investigation, although there is a large number of data indicating that the synergism between probiotics and prebiotics favours the survival and implantation of probiotics into the gastrointestinal tract with beneficial effects on human health by modulating the inflammatory response and gut microbiota composition. The aim of this minireview is to describe the main in vitro, animal and human studies performed up to now, that have used synbiotics to treat ulcerative colitis, and to highlight limitations and future perspectives.
Keywords: Inflammatory bowel disease, ulcerative colitis, synbiotics, inflammation, probiotics, prebiotics, immune system, microbiota.
Graphical Abstract
Current Clinical Pharmacology
Title:Use of Synbiotics for Ulcerative Colitis Treatment
Volume: 15 Issue: 3
Author(s): Marianna Roselli and Alberto Finamore*
Affiliation:
- CREA Research Centre for Food and Nutrition, Rome,Italy
Keywords: Inflammatory bowel disease, ulcerative colitis, synbiotics, inflammation, probiotics, prebiotics, immune system, microbiota.
Abstract: Inflammatory bowel diseases, namely Crohn's disease and ulcerative colitis, are currently considered multifactorial pathologies in which various combined environmental factors act on genetic background, giving rise to chronic inflammation of the gastrointestinal tract. Ulcerative colitis is an inflammation of the colon caused by a dysregulated immune response to host intestinal microbiota in genetically susceptible subjects. Ulcerative colitis has a strong impact on patients' quality of life, as well as high costs for the health-care system. A great interest on the role of intestinal microbiota modulation in ulcerative colitis is emerging. Several studies have shown an improvement of inflammatory markers and symptoms in ulcerative colitis patients through treatments with probiotics and prebiotics separately. Despite the low number of studies on the treatment of ulcerative colitis by specific strains of probiotics plus selected prebiotics, i.e. synbiotics, the results are promising, even if discordant. The mechanism of action in synbiotics supplementation is still unclear and needs more investigation, although there is a large number of data indicating that the synergism between probiotics and prebiotics favours the survival and implantation of probiotics into the gastrointestinal tract with beneficial effects on human health by modulating the inflammatory response and gut microbiota composition. The aim of this minireview is to describe the main in vitro, animal and human studies performed up to now, that have used synbiotics to treat ulcerative colitis, and to highlight limitations and future perspectives.
Export Options
About this article
Cite this article as:
Roselli Marianna and Finamore Alberto *, Use of Synbiotics for Ulcerative Colitis Treatment, Current Clinical Pharmacology 2020; 15 (3) . https://dx.doi.org/10.2174/1574884715666191226120322
DOI https://dx.doi.org/10.2174/1574884715666191226120322 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Color Doppler Ultrasound Assessment of Clinical Activity in Inflammatory Bowel Disease
Current Medical Imaging Polymeric Drug Delivery Approaches for Colon Targeting: A Review
Drug Delivery Letters Ulcerative Colitis: Pathogenesis
Current Drug Targets Diagnosis of Inflammatory Bowel Disease by Abdominal Ultrasound and Color Doppler Techniques
Current Medical Imaging Alternative Therapy in the Prevention of Experimental and Clinical Inflammatory Bowel Disease. Impact of Regular Physical Activity, Intestinal Alkaline Phosphatase and Herbal Products
Current Pharmaceutical Design Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?
Inflammation & Allergy - Drug Targets (Discontinued) Signaling Pathways Associated with Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Colon as Target for Drug Delivery
Current Drug Therapy Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease
Reviews on Recent Clinical Trials Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Guar Gum and HPMC Coated Colon Targeted Delivery of 6-Mercapto-Purine
The Natural Products Journal Cytokines, Inflammation and Colon Cancer
Current Cancer Drug Targets Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery Desirability Based Optimization of New Mesalazine Modified Release Formulations: Compression Coated Tablets and Mini Tablets in Capsules
Letters in Drug Design & Discovery Macrophages in Inflammatory Bowel Disease
Current Drug Targets - Inflammation & Allergy New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA